Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 6
2004 2
2005 6
2006 6
2007 2
2008 4
2009 1
2010 10
2011 10
2012 7
2013 9
2014 16
2015 21
2016 19
2017 12
2018 11
2019 11
2020 20
2021 20
2022 22
2023 16
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ; DECISION investigators. Brose MS, et al. Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24. Lancet. 2014. PMID: 24768112 Free PMC article. Clinical Trial.
Opioid-induced constipation.
Gyawali B, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y. Gyawali B, et al. Among authors: ando y. Scand J Gastroenterol. 2015;50(11):1331-8. doi: 10.3109/00365521.2015.1054423. Epub 2015 Jun 10. Scand J Gastroenterol. 2015. PMID: 26061717 Review.
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events.
Schöffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, Wagner JP, Mansfield K, Zhu X, Origuchi S, DiDominick S, Bialucha CU, Faris JE, Tran B. Schöffski P, et al. Among authors: ando y. Oncol Res Treat. 2021;44(10):547-556. doi: 10.1159/000518549. Epub 2021 Aug 19. Oncol Res Treat. 2021. PMID: 34515215 Free article. Clinical Trial.
Consent in Pharmacogenetic Testing.
Ando Y, Terada T. Ando Y, et al. J Clin Oncol. 2023 Aug 1;41(22):3875. doi: 10.1200/JCO.23.00664. Epub 2023 Jun 2. J Clin Oncol. 2023. PMID: 37267582 No abstract available.
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Ando Y, et al. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. Int J Clin Oncol. 2023. PMID: 37453935
[Chemotherapy for Older Patients with Cancer].
Mitsuma A, Ando Y. Mitsuma A, et al. Among authors: ando y. Gan To Kagaku Ryoho. 2022 Jan;49(1):13-18. Gan To Kagaku Ryoho. 2022. PMID: 35046353 Japanese.
Carboplatin dosing for adult Japanese patients.
Ando Y, Shimokata T, Yasuda Y, Hasegawa Y. Ando Y, et al. Nagoya J Med Sci. 2014 Feb;76(1-2):1-9. Nagoya J Med Sci. 2014. PMID: 25129986 Free PMC article. Review.
Guidelines for treatment of renal injury during cancer chemotherapy 2016.
Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, Takaishi H, Shimodaira H, Mogi A, Ando Y, Matsumoto K, Kadowaki D, Muto S. Horie S, et al. Among authors: ando y. Clin Exp Nephrol. 2018 Feb;22(1):210-244. doi: 10.1007/s10157-017-1448-z. Clin Exp Nephrol. 2018. PMID: 28856465 Free PMC article. Review. No abstract available.
FDA Approval Summary: Sonidegib-Letter.
Gyawali B, Ando Y. Gyawali B, et al. Among authors: ando y. Clin Cancer Res. 2017 Oct 1;23(19):5993. doi: 10.1158/1078-0432.CCR-17-1460. Clin Cancer Res. 2017. PMID: 28972085 No abstract available.
211 results